Innovations in RNA Delivery

This chapter explores the strategic decisions of a biotechnology company focusing on antisense oligonucleotide therapies, detailing the speaker's transition to CEO and their innovative use of antibody oligonucleotide conjugates. It emphasizes the importance of scientific data in advancing therapies for muscle diseases and highlights the company's unique approach to RNA technology.